Johnson & Johnson announced it will buy Intra-Cellular Therapies for $14.6 billion. Biogen said it will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics ... including one involving another oncology biotech—that of the Johnson and Johnson acquiring Intracellular Therapies.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Eli Lilly's operational performance is strong, but shares are expensive, leading me to reaffirm a 'hold' rating despite potential upside from new drugs. Recent financial results show significant ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn ... s Skyrizi and an expected approval for Johnson & Johnson’s Tremfya raises questions about ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...